PHARMANOVIA
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its endocrinology portfolio with a new licensing agreement for GHRYVELIN™ (macimorelin), a novel medicine used for diagnosing Adult Growth Hormone Deficiency (AGHD) from Aeterna Zentaris.
The agreement gives Pharmanovia the exclusive commercial rights in the UK and EEA.
AGHD is a rare and serious condition that affects 2 to 3 people in 10,000 with significant risk of morbidity and reduced quality of life. It is underdiagnosed and often missed in patients.1
It is characterised by a number of variable and common symptoms including reduced energy levels, altered body composition, osteoporosis (reduced bone mineral density), reduced muscle strength, lipid abnormalities such as increased LDL cholesterol, insulin resistance, and impaired cardiac function.2
Pharmanovia CEO, Dr James Burt commented; ‘’Endocrinology is the largest of our four core therapy areas and the in-licensing of this important novel medicine, the second in-licensing deal of a novel medicine in almost as many weeks, speaks to our ability to in-licence novel, complementary products in the therapeutic settings we support.”
“We are well placed to use the knowledge and the platform we’ve built through our current endocrinology work to ensure that more patients get the diagnosis they need for this rare and serious condition. Furthermore today’s announcement presents a rare opportunity to license in a medicine that naturally synergises with one of the core growth products in our current portfolio.”
Dr Klaus Paulini, CEO of Aeterna Zentaris, added: “Pharmanovia has expertise marketing diagnostic testing solutions combined with an established footprint in endocrinology across Europe, so this partnership was a natural choice. We’re excited to leverage their knowledge to ensure that more patients benefit from an improved testing experience and reduction in unnecessary treatment for patients.”
About Pharmanovia
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by enhancing established medicines either by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and through strategic partnerships.
Our diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company developing and commercialising a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen™; Ghryvelin®), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need, in collaboration with Novo Nordisk.
About Macimorelin
Macimorelin is marketed under the brand name GHRYVELIN™ (macimorelin) in the UK and European Economic Area.
GHRYVELIN™ a ghrelin agonist, is an orally active small molecule that stimulates the secretion of growth hormone from the pituitary gland. Stimulated growth hormone levels are measured in blood samples after oral administration of GHRYVELIN™ for the assessment of AGHD. of GHRYVELIN™ was granted in 2019, based on Phase III data showing that oral macimorelin provides accuracy comparable to that of standard insulin tolerance testing (ITT)4, but has a more favourable safety profile compared to ITT. Oral GHRYVELIN™ also reduces false positive test results, helping to avoid unnecessary treatment of patients.3
References
1 J Endocr Soc. 2022 Jul 1; 6(7): bvac077. Andrew R Hoffman, Tracy Mathison, Deno Andrews, Kristine Murray, Nicky Kelepouris, and Maria Fleseriu - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165431/ -last accessed 1.3.2023
2 Yuen KCJ, Biller BMK, Radovick S, et al -. Endocr Pract. 2019;25(11):1191-1232. https://pubmed.ncbi.nlm.nih.gov/31760824/ - last accessed 1.3.2023
3 Garcia JM et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab, 2018, 103(8): 3083-3093 - https://pubmed.ncbi.nlm.nih.gov/29860473/ - last accessed 1.3.2023
4 https://www.ema.europa.eu/en/documents/assessment-report/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-public-assessment-report_en.pdf – last accessed 1.3.2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005846/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
INNIO wins prestigious German Sustainability Award 20269.12.2025 09:07:00 CET | Press release
INNIO Group has been awarded the German Sustainability Award for Companies 2026. At the 18th annual ceremony in Düsseldorf, INNIO was named winner in the “Engines and Turbines” category within the “Machines and Installations” sector. Recognized as one of Europe’s most respected distinctions for corporate responsibility, the German Sustainability Award reflects the United Nations’ Agenda 2030 and thus on the key areas of transformation such as climate, biodiversity, resources, supply chain, and society. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205520809/en/ INNIO wins prestigious German Sustainability Award 2026 (c) Frank Fendler “This award is a tremendous recognition for our entire team and validates our 360-degree approach to sustainable innovation throughout the value chain,” said Marcin Kawa, VP Sustainability at INNIO Group. “We are committed to actively shaping the energy transition and delivering solutions th
EURONICS and NIQ Forge Strategic Collaboration to Elevate Retail Pricing Intelligence9.12.2025 09:00:00 CET | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company combined with GfK in 2023, has been selected by EURONICS, a leading global shopping cooperative in the Technical Consumer Goods (TCG) sector, to provide comprehensive Online Price Monitoring. NIQ's Online Price Monitoring provides insights into pricing dynamics by tracking item-level pricing across a defined data set. The system captures product information, matches items accurately, and ensures quality through advanced automated processes combined with human oversight and detailed checks. NIQ offers a range of retail pricing solutions, including pricing intelligence tools and the Consumer Price Lab, empowering businesses to make informed decisions and optimize their pricing strategies. This collaboration focuses on providing EURONICS with comprehensive pricing insights to support informed decision-making. NIQ delivers accurate and transparent data to help EURONICS understand market dynamics and plan effectively. "Through our col
SonicEdge and Earfab Partner to Shape the Future of Personalized Audio and Hearing Wellness9.12.2025 09:00:00 CET | Press release
Partnership unites SonicEdge’s micro-speaker technology with Earfab’s custom-fit innovation to deliver unmatched comfort and fidelity SonicEdge, a pioneer in micro-acoustic innovation, today announced a strategic partnership with Earfab, the innovator of custom-fit hearing technology, to co-develop a new generation of personalized audio solutions that unite comfort, precision, and hearing safety. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209472421/en/ Credit: SonicEdge By combining SonicEdge’s high-performance MEMS speaker-in-chip technology with Earfab’s custom-fit eartips – crafted using its proprietary earfabSCAN 3D smartphone scanning platform – the collaboration delivers a first-of-its-kind experience that redefines in-ear performance. The joint solution provides a perfect acoustic seal for enhanced sound fidelity, improved active noise cancellation, and long-term listening comfort – without compromising hearing
Outpost24 Acquires Infinipoint to Power Its Entry into the Zero Trust Workforce Access Market9.12.2025 08:00:00 CET | Press release
The strategic acquisition strengthens market leadership by unifying user identity with device trust, eliminating security blind spots. Outpost24, a leader in exposure management and identity security, today announced the acquisition of Infinipoint, a specialist in device identity, posture validation, and secure workforce access. The acquisition marks Outpost24’s entry into the Zero Trust Workforce Access market and enhances its identity security division, Specops, by laying the foundation for a unified approach that evaluates both the user and the device before access is granted. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208750630/en/ Ido Erlichman, Chief Executive Officer of Outpost24. As organizations advance their Zero Trust strategies, authentication alone is no longer enough. MFA and SSO confirm who the user is, but they do not validate the security of the device being used. In hybrid environments where employee
VSO Submits VCP v1.0 to Nineteen Regulatory Authorities Across Thirteen Jurisdictions and Completes First Integrated Evaluation in a Production-Like Environment9.12.2025 08:00:00 CET | Press release
The VeritasChain Standards Organization (VSO) announced today that it has submitted the VeritasChain Protocol (VCP) v1.0 to nineteen regulatory authorities across thirteen jurisdictions, including the United States, United Kingdom, European Union, Singapore, Hong Kong, United Arab Emirates (DIFC), Australia, India, South Korea, Switzerland, Brazil, Liechtenstein, and Saudi Arabia. The submissions present VCP v1.0 as a cryptographic audit framework designed to address emerging supervisory requirements under the EU AI Act Article 12 for logging and traceability, and MiFID II / RTS 25 for timestamp integrity and event ordering in AI-driven and algorithmic trading systems. VSO also confirmed the first completed integration of VCP v1.0 within a controlled, production-like evaluation environment operating under its Early Access Program. The environment successfully generated cryptographically linked event chains, immutable hashing, and verifiable proofs using RFC-aligned structures, demonstr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom